21 Jul 2025 Harm profile of JAK inhibitors in ulcerative colitis
This report reviews open-label randomized and non-randomized experimental studies as well as observational studies of harm associated with the Janus kinase inhibitors (JAKi) tofacitinib and upadacitinib for ulcerative colitis in the post authorization time period.
Click on the ‘Download‘ button to view or download the report (PDF format).
No Comments